1. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia: long term follow-up of a controlled trial. Blood 1989; 73: 1729–1734.
2. Rindgen O, Labopin M, Gluckman E et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipient with acute leukemia is maintained using cyclosporine A combined with methotrexate as prophylaxis. Bone Marrow Transplantation 1996; 18: 921–929.
3. Locatelli F, Bruno B, Zecca M et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690–1697.
4. Deeg HJ, Spitzer TR, Cottler-Fox M et al. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplantation 1991; 7: 193–198.
5. Atkinson K, Downs K . Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation. Bone Marrow Transplantation 1995; 16: 755–758.